Q4 2017 EPS Estimates for Sarepta Therapeutics, Inc. (SRPT) Reduced by Analyst

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – SunTrust Banks dropped their Q4 2017 earnings per share estimates for shares of Sarepta Therapeutics in a note issued to investors on Tuesday. SunTrust Banks analyst E. Nash now anticipates that the biotechnology company will post earnings of ($0.73) per share for the quarter, down from their prior estimate of ($0.69). SunTrust Banks has a “Buy” rating and a $56.00 price target on the stock.

Other research analysts also recently issued research reports about the company. Credit Suisse Group set a $64.00 price objective on Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Leerink Swann reaffirmed a “buy” rating and issued a $60.00 price objective (up previously from $52.00) on shares of Sarepta Therapeutics in a research note on Tuesday, July 18th. BidaskClub raised Sarepta Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a research note on Thursday, June 22nd. Finally, Nomura reaffirmed a “buy” rating and issued a $84.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, September 5th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $64.34.

COPYRIGHT VIOLATION WARNING: “Q4 2017 EPS Estimates for Sarepta Therapeutics, Inc. (SRPT) Reduced by Analyst” was originally published by Stock Observer and is the property of of Stock Observer. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2017/10/13/q4-2017-eps-estimates-for-sarepta-therapeutics-inc-srpt-reduced-by-analyst.html.

Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded down 1.090% during midday trading on Thursday, hitting $50.721. The stock had a trading volume of 208,992 shares. The firm’s market cap is $3.26 billion. Sarepta Therapeutics has a 12 month low of $26.26 and a 12 month high of $55.02. The stock’s 50 day moving average price is $45.30 and its 200 day moving average price is $36.94.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.92) by $0.46. The company had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. During the same quarter in the prior year, the company earned ($1.19) earnings per share. The company’s quarterly revenue was up 350000.0% on a year-over-year basis.

In other Sarepta Therapeutics news, CFO Sandesh Mahatme sold 50,000 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, July 20th. The stock was sold at an average price of $41.00, for a total value of $2,050,000.00. Following the sale, the chief financial officer now owns 41,736 shares of the company’s stock, valued at approximately $1,711,176. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Shamim Ruff sold 11,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Tuesday, October 3rd. The stock was sold at an average price of $50.00, for a total value of $575,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 89,556 shares of company stock worth $3,799,208. Corporate insiders own 9.60% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 1.4% in the 1st quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock worth $280,000 after purchasing an additional 129 shares during the period. Ameritas Investment Partners Inc. boosted its holdings in shares of Sarepta Therapeutics by 6.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after purchasing an additional 271 shares during the period. Advisor Group Inc. boosted its holdings in shares of Sarepta Therapeutics by 3.2% in the 2nd quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after purchasing an additional 326 shares during the period. Legal & General Group Plc boosted its holdings in shares of Sarepta Therapeutics by 3.9% in the 2nd quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after purchasing an additional 663 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its holdings in shares of Sarepta Therapeutics by 0.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after purchasing an additional 818 shares during the period. 65.41% of the stock is currently owned by institutional investors and hedge funds.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Earnings History and Estimates for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply